Narrows FY24 adjusted EBITDA view to $13M-$14M from $13M-$15M. “LifeMD (LFMD) had a strong quarter with top- and bottom-line growth led by our core telehealth business. Not only did this business achieve 65% year-over-year growth on a standalone basis and patient subscriber base grew to approximately 269,000 at quarter-end, but telehealth adjusted EBITDA increased 200% sequentially to $2.5 million. Although WorkSimpli’s financial results continued to be pressured, the business returned to sequential subscriber growth and is still forecasted to reach peak monthly profitability by year-end,” commented Marc Benathen, Chief Financial Officer of LifeMD. “Cash flow continued to increase and remained exceptionally strong. For the third quarter, LifeMD generated over $6 million of operating cash flow and bolstered its cash balance by approximately $2 million to $37.6 million as of September 30th. Our strong unit economics, consistent cash flow generation and strengthened balance sheet continue to support our ability to optimize our corporate investment needs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD reports Q3 EPS (14c), consensus (12c)
- LifeMD launches affiliated pharmacy to drive end-to-end patient care
- LifeMD launches TestoRx, direct to consumer testosterone replacement therapy
- BTIG says market demand for lower cost GLP1-s should benefit LifeMD, Him & Hers
- LifeMD announces major enhancements to its weight management program